{"entity":{"id":"nct00066703","kind":"trial","name":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","aka":[],"tldr":"A phase 3 trial of Tamoxifen and Triptorelin in Breast cancer, run by ETOP IBCSG Partners Foundation, completed.","summary":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer is a phase 3 interventional study registered as NCT00066703 by ETOP IBCSG Partners Foundation, with 2672 participants recorded, started 2003-11-03 and reaching its primary completion in 2011-03-11. Interventions recorded: exemestane, tamoxifen, triptorelin. Conditions recorded: Breast Cancer.\n\nLinked to the drug Triptorelin because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00066703","url":"https://clinicaltrials.gov/study/NCT00066703"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tamoxifen","triptorelin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00066703","phase":"3","setting":"A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer","sponsor":"ETOP IBCSG Partners Foundation","enrolled":2672,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00066703/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"},{"id":"triptorelin","kind":"drug","name":"Triptorelin","route":"/drugs/triptorelin/"}]}}